Crude and adjusted relative risk calculations for mutation prevalence and drug resistance call between different groups.

Log-binomial regression analysis was used and the model was adjusted with CD4, VL and time on treatment where possible. Adjusted relative risk was only calculated for N: Number of patients; RR: relative risk; CI: confidence interval; VL: RNA Viral Load; ART: antiretroviral treatment; 3TC: lamivudine; FTC: emtricitabine; ABC: abacavir; AZT: zidovudine; d4T: stavudine; ddI: didanosine; TDF: tenofovir; EFV: efavirenz; ETR: etravirine; NVP: nevirapine; RPV: rilpivirine; S: susceptible; IR: intermediate resistance; HR: high-level resistance; ND: not done
Crude and adjusted relative risk calculations for mutation prevalence and drug resistance call between different groups.